** COVID-19 | Stelis Biopharma to make 200 million doses of Russian Sputnik V vaccine

The Russian Direct Investment Fund (RDIF), the country’s sovereign wealth fund, and Stelis Biopharma, the biopharmaceutical division of Bengaluru-based Strides Pharma, have entered into a partnership to produce and supply a minimum of 200 million doses (enough to vaccinate 100 million people) of the Russian Sputnik V vaccine against coronavirus.

Leave a Reply

Your email address will not be published. Required fields are marked *